Squarepoint Q2 Portfolio Expansion
Squarepoint Ops Increases Its Holdings Across Five Publicly Traded Companies in Q2
Anonymous
Key Points
1
At BeOne Medicines, CEO John Oyler sold 145,861 shares at an average price of $305.95 for proceeds of about $44.6 million; the transaction reduced his direct ownership by 94.73%.
2
Squarepoint’s Exelixis increase involved purchasing 446,635 additional shares during the quarter, bringing its position to 473,707 shares valued at approximately $25.8 million.
3
Legend Biotech received a mixed analyst signal during the period: Royal Bank of Canada lowered its price target from $59 to $58 while retaining an “outperform” rating.
4
UniFirst shares were trading at $275.26, with a market capitalization of about $4.98 billion, a price-to-earnings ratio of 43.42 and a 52-week range of $147.66 to $306.67.
Squarepoint Ops LLC aggressively expanded its stock portfolio during the second quarter, boosting holdings in five publicly traded companies. The hedge fund's most dramatic move was a 1,649.8% surge in Exelixis shares to 473,707, valued at roughly $25.8 million, according to Watchlist News. Squarepoint also raised positions in UniFirst by 75.8%, Legend Biotech by 60.4%, Molson Coors by 8.1%, and BeOne Medicines by 6%, signaling a broad bet on industrial, consumer, and biotech stocks.
The moves coincide with institutional buying pressure from major firms like BlackRock, though insider activity tells a contrasting story. BeOne Medicines CEO John Oyler sold 145,861 shares for $44.6 million at an average price of $305.95, slashing his direct ownership by 94.73%, according to SEC Form 4 filings. Meanwhile, analyst Royal Bank of Canada lowered its Legend Biotech price target from $59 to $58 while keeping an "Outperform" rating, reflecting cautious optimism amid valuation pressure.
Massive Exelixis Bet Signals Oncology Confidence
Squarepoint's 1,649.8% increase in Exelixis—buying 446,635 additional shares during the quarter—marks its most aggressive move. The position now totals 473,707 shares valued at approximately $25.8 million, according to Watchlist News. The surge reflects a concentrated institutional bet on oncology drug commercialization and cash-flow expansion, targeting a stage where the biotech company transitions from development into broad market adoption.
UniFirst and Molson Coors Attract Defensive Capital
Squarepoint raised its UniFirst stake by 75.8% to 107,196 shares, joining BlackRock in establishing or expanding positions in the uniform and textile-services provider, per Watchlist News. UniFirst shares traded at $275.26 with a market cap of $4.98 billion and a price-to-earnings ratio of 43.42. The 52-week range spanned $147.66 to $306.67, reflecting the stock's strong year.
Molson Coors—a consumer staple brewer—saw Squarepoint's position grow 8.1% to 1.19 million shares. Both moves suggest the hedge fund is rebalancing toward defensive cash-flow generators that weather economic uncertainty better than high-growth stocks. Institutional investors now control substantial portions of outstanding shares across both companies.
BeOne CEO Liquidates 95% Stake Despite Fund Buying
While Squarepoint increased its BeOne Medicines stake by 6% to 78,561 shares, CEO John Oyler moved sharply in the opposite direction. On July 14, Oyler sold 145,861 shares at an average price of $305.95, netting $44.6 million and slashing his direct ownership by 94.73%, according to SEC Form 4 filings. The dramatic insider sale creates tension between institutional accumulation and executive sentiment.
Oyler cited BeOne's mission in public statements: "We believe every patient should benefit from innovative cancer therapies." Yet the sale raises questions about C-suite confidence levels. Institutional investors holding large blocks can preserve voting power through indirect channels even after direct stake reductions, complicating the interpretation of insider moves.
Legend Biotech Draws Hedges Despite Analyst Confidence
Squarepoint boosted its Legend Biotech position by 60.4% to 769,252 shares during Q2. Royal Bank of Canada's equity research team lowered the price target from $59 to $58 per share but retained an "Outperform" rating, signaling underlying confidence in the cell-therapy firm's commercialized CAR-T pipeline. The price-target cut reflects macro valuation pressure rather than fundamental deterioration.
The mismatch between institutional buying and sell-side price-target reductions highlights Wall Street's cautious optimism. Analysts believe in Legend's long-term oncology story but acknowledge near-term headwinds. Squarepoint's aggressive accumulation suggests the fund sees value beneath current pricing despite analyst trimming.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
69
Articles
108
Reach
177
A
AnonymousAuthor
